Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 19

1.

FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.

Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Sartangi NF, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD.

PLoS One. 2013;8(1):e53190. doi: 10.1371/journal.pone.0053190. Epub 2013 Jan 24.

2.
3.

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.

Langdon WY.

Crit Rev Oncog. 2012;17(2):199-209. Review.

PMID:
22471708
4.
5.

FLT3 inhibition in acute myeloid leukaemia.

Knapper S.

Br J Haematol. 2007 Sep;138(6):687-99. Epub 2007 Jul 26. Review.

PMID:
17655729
6.
7.

The role of FLT3 kinase as an AML therapy target.

Beffinger M, Skwarska A.

Curr Pharm Des. 2012;18(19):2758-65. Review.

PMID:
22390761
8.

FLT3 inhibitors for the treatment of acute myeloid leukemia.

Wiernik PH.

Clin Adv Hematol Oncol. 2010 Jun;8(6):429-36, 444. Review.

PMID:
20733555
9.

FLT3 as a therapeutic target in childhood acute leukemia.

Stubbs MC, Armstrong SA.

Curr Drug Targets. 2007 Jun;8(6):703-14. Review.

PMID:
17584026
10.

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Levis M.

Hematology Am Soc Hematol Educ Program. 2013;2013:220-6. doi: 10.1182/asheducation-2013.1.220. Review.

11.

Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.

Paganin M, Ferrando A.

Blood Rev. 2011 Mar;25(2):83-90. doi: 10.1016/j.blre.2010.09.004. Epub 2010 Oct 20. Review.

12.

Early T-cell precursor acute lymphoblastic leukaemia.

Haydu JE, Ferrando AA.

Curr Opin Hematol. 2013 Jul;20(4):369-73. doi: 10.1097/MOH.0b013e3283623c61. Review.

13.

Secondary mutations as mediators of resistance to targeted therapy in leukemia.

Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H.

Blood. 2015 May 21;125(21):3236-45. doi: 10.1182/blood-2014-10-605808. Epub 2015 Mar 20. Review.

14.

Novel targeted therapies in acute lymphoblastic leukemia.

Portell CA, Advani AS.

Leuk Lymphoma. 2014 Apr;55(4):737-48. doi: 10.3109/10428194.2013.823493. Epub 2013 Aug 28. Review.

PMID:
23841506
15.

Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia.

Chonabayashi K, Hishizawa M, Matsui M, Kondo T, Ohno T, Ishikawa T, Takaori-Kondo A.

Ann Hematol. 2014 Mar;93(3):535-7. doi: 10.1007/s00277-013-1843-9. Epub 2013 Jul 20. Review. No abstract available.

PMID:
23873282
16.

The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemia.

Tremblay CS, Curtis DJ.

Curr Opin Hematol. 2014 Jul;21(4):320-5. doi: 10.1097/MOH.0000000000000058. Review.

PMID:
24857886
17.

Novel approaches to pediatric leukemia treatment.

Thomas X.

Expert Rev Anticancer Ther. 2015;15(7):811-28. doi: 10.1586/14737140.2015.1047769. Epub 2015 May 23. Review.

PMID:
26004287
18.

[Acute lymphoblastic leukemia of T progenitors: from biology to clinics].

Genescà E, Ribera J, Ribera JM.

Med Clin (Barc). 2015 Mar 9;144(5):223-9. doi: 10.1016/j.medcli.2014.01.029. Epub 2014 Mar 22. Review. Spanish.

PMID:
24667111
19.

The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) - Mechanisms and Opportunities.

Bernt KM, Hunger SP, Neff T.

Front Pediatr. 2016 May 18;4:49. doi: 10.3389/fped.2016.00049. eCollection 2016. Review.

Items per page

Supplemental Content

Write to the Help Desk